Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

The Journal of infectious diseases - 1 Feb 2013

Ribaudo Heather J, Daar Eric S, Tierney Camlin, Morse Gene D, Mollan Katie, Sax Paul E, Fischl Margaret A, Collier Ann C, Haas David W

Abstract excerpt

The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/la...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Glucuronosyltransferase

Share to Jaundice

Share to Oligopeptides

Share to Pyridines

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 23148286
DOI: 10.1093/infdis/jis690
PMCID: PMC3537445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-23148286-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.PMID 23148286Read ↗

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.Semantic proximity Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.Semantic proximity Read ↗

Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.Semantic proximity Read ↗

Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.Semantic proximity Read ↗

Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.Semantic proximity Read ↗

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.Semantic proximity Read ↗

Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.